Supreme Court Rebalances Skinny-Label Risk: What Hikma v. Amarin Means for ANDA Strategy

The Supreme Court’s unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. is one of the most important Hatch-Waxman decisions for generic drug launch planning in years. The Court reversed the Federal Circuit and held that Amarin had not plausibly pleaded that Hikma actively induced infringement of Amarin’s cardiovascular-risk-reduction method patents after Hikma launched a generic version of Vascepa with a so-called skinny label. The ruling does not eliminate induced-infringement risk for Abbreviated New Drug Application (ANDA) applicants, but it gives generic manufacturers more room to rely on the Section viii carveout pathway without every statement about generic equivalence, AB rating, or product availability becoming a litigation trigger.

The decision matters because it sits at the intersection of patent law, FDA labeling rules, state substitution laws, and the commercial realities of generic launch. Under the Hatch-Waxman framework, an Abbreviated New Drug Application allows a generic company to rely on the branded drug’s safety and efficacy findings rather than repeat full clinical trials, provided the generic shows the required sameness and bioequivalence. That framework becomes more complicated when the branded drug has both patented and unpatented uses.

The dispute

Amarin’s Vascepa was first approved for a severe-hypertriglyceridemia indication and later for a broader cardiovascular-risk-reduction indication. Hikma filed an ANDA for generic icosapent ethyl and, after Amarin’s patents covering the original severe-hypertriglyceridemia use were invalidated, pursued approval with a skinny label that omitted the patented cardiovascular-risk-reduction use. FDA approved Hikma’s generic product in 2020 and assigned it an AB rating.

Amarin sued, alleging that Hikma’s label, patient materials, website, press releases, and market statements encouraged doctors to prescribe the generic product for Amarin’s patented cardiovascular indication. The district court dismissed the complaint, but the Federal Circuit revived it. The Supreme Court then reversed, holding that Amarin’s allegations did not plausibly show active inducement.

The Court’s central point was straightforward: induced infringement requires more than knowledge that a generic drug may be used in an infringing way. It requires affirmative conduct that encourages infringement. In the skinny-label setting, the question is not simply whether doctors could read a generic company’s statements as consistent with the patented use. The question is whether the generic company actively encouraged that use.

The Court’s message to the Federal Circuit

The Court rejected a pleading approach that placed too much weight on whether generic labeling or communications could be interpreted by physicians as pointing toward the patented use. In the Court’s view, that standard risks converting ordinary conduct associated with lawful generic marketing into evidence of inducement. The Court emphasized that ordinary distribution, lawful statements about generic equivalence, and FDA-required or industry-standard communications are not enough by themselves.

That is the most important doctrinal move in the opinion. The Court did not create a categorical safe harbor for generics. It acknowledged that inducement can be implicit, not only express. But the encouragement must still be clear and affirmative. Vague language, omissions from a skinny label, market realities, and speculation about how physicians may respond will not carry a complaint past the pleading stage unless they plausibly show that the generic manufacturer itself encouraged infringing use.

Implications for ANDA applicants

For generic manufacturers, Hikma strengthens the practical value of the Section viii pathway. A skinny label is supposed to permit approval for non-patented uses while leaving patented uses off the generic label. Before Hikma, the Federal Circuit’s approach created concern that even a carefully carved-out label could invite costly induced-infringement litigation if the generic’s product was substitutable for the brand and if public materials described the product as a generic equivalent. The Supreme Court’s decision reduces that risk.

That said, Hikma is not a license for careless launch communications. Generic companies should treat the ruling as a litigation-risk-management decision, not as blanket immunity. A company that trains sales representatives to discuss a carved-out use, publishes materials that highlight clinical benefits tied to the patented indication, uses search terms or web content aimed at the patented patient population, or circulates payer and physician materials that effectively reinsert the carved-out indication may still face a viable inducement claim.

The safest generic strategy after Hikma is disciplined consistency. The FDA label, website, product catalog, press releases, investor materials, sales training, medical-information responses, payer communications, and distributor materials should all align with the approved skinny label. Statements about AB rating and generic equivalence should be accurate, conventional, and tied to the approved labeling. Where appropriate, companies should consider clarifying that the product is approved only for the non-carved-out indication, especially in contexts where the audience may otherwise infer broader promotion.

The ruling also gives ANDA filers a stronger basis for early motions to dismiss. When a brand’s complaint relies mainly on FDA approval, AB rating, state substitution, sales volume, or generalized statements that the product is a generic equivalent, the generic defendant can now argue that those allegations describe lawful participation in the Hatch-Waxman system rather than active inducement. The Court’s opinion should make it harder for brand plaintiffs to use thin inducement theories to obtain discovery and increase settlement pressure.

Implications for brand companies

For brand manufacturers, the decision raises the pleading bar. A complaint that merely alleges that doctors know the generic can be substituted, or that the generic company knows some prescriptions may be for the carved-out use, is unlikely to be enough. The Court made clear that knowledge of downstream infringing use is different from encouraging that use.

Brand plaintiffs will need a more evidence-driven approach. Before filing, they should identify concrete statements or actions by the generic company that point specifically to the patented use. Useful evidence may include sales scripts, field communications, physician-facing materials, payer presentations, formulary materials, website content, search advertising, medical-information responses, conference materials, or distributor communications that connect the generic product to the protected indication.

The complaint should then plead inducement with precision: what the generic said, who said it, to whom it was directed, when it was made, how it maps to the patent claims, and why it would cause direct infringement. After Hikma, brand plaintiffs should expect courts to scrutinize whether alleged statements are truly promotional encouragement of the patented use or merely ordinary statements about a lawfully approved generic product.

The decision also has implications for patent prosecution and Orange Book strategy. Method-of-use patents remain valuable, but they are more difficult to enforce against a skinny-label generic when the generic can carve out the patented indication cleanly. Brand companies may respond by paying closer attention to use codes, label language, claim drafting, continuation strategy, and whether patent claims map to unavoidable portions of the generic label. At the same time, overly broad use codes can create their own regulatory and litigation problems, so the brand strategy must be precise rather than simply aggressive.

Litigation strategy after Hikma

For generics, the litigation playbook now begins earlier in the regulatory process. ANDA applicants should document the basis for the Section viii carveout, preserve communications with FDA, and maintain a record showing that the proposed label avoids the patented use. Before launch, they should conduct a privilege-protected review of external communications and train commercial, regulatory, investor-relations, and medical-affairs teams on the boundaries of the approved indication.

In litigation, generic defendants should move quickly to frame the case around the Supreme Court’s distinction between passive market consequences and affirmative encouragement. AB rating, generic equivalence, substitution laws, and sales data are features of the Hatch-Waxman marketplace. Without more, they should not become evidence of inducement. The strongest defense will show that the challenged statements were accurate, standard, label-consistent, and directed to lawful uses.

For brands, the playbook shifts toward pre-suit investigation and targeted pleading. A successful inducement complaint should not rely on the mere fact that prescriptions are likely to occur for the carved-out use. It should allege affirmative conduct by the generic manufacturer that was designed to cause that use. Brands should also consider whether their dispute is really about the adequacy of the carveout, FDA labeling, Orange Book use codes, or patent scope, rather than trying to force those issues into an inducement theory.

Industry-wide consequences

The broader effect of Hikma is likely to be increased confidence in skinny-label launches, especially for drugs with multiple indications and later-added method-of-use patents. Generic companies may be more willing to use Section viii carveouts where the patented use can be separated from unpatented uses. That could accelerate generic entry for some products and reduce the settlement value of infringement theories based mainly on substitution and market leakage.

But the decision will not end skinny-label litigation. Instead, it will change what the cases are about. Future disputes will likely focus less on whether a generic product is substitutable and more on whether the generic company’s own words or actions crossed the line into active encouragement. In that sense, Hikma shifts the battlefield from the mere existence of a skinny-label launch to the quality and content of the generic’s launch communications.

The Supreme Court’s opinion is therefore best understood as a recalibration. It protects the Section viii pathway from being undermined by overbroad inducement theories, but it preserves liability for true off-label promotion of patented uses. For the generic industry, that is a meaningful win. For brand companies, it is a warning that post-launch patent enforcement must be built on concrete evidence of encouragement, not on the predictable operation of the generic substitution system.

The practical takeaway is simple: after Hikma, skinny labels are stronger, but compliance discipline matters more than ever. Generic companies should launch with cleaner labels, cleaner communications, and cleaner records. Brand companies should litigate with sharper facts, sharper pleadings, and sharper patent strategies. The winners in the next wave of ANDA litigation will be the companies that understand that Hikma is not just a patent case; it is a roadmap for how regulatory strategy, commercial messaging, and litigation strategy must work together.

Chris Z. Liu is a Director in Fennemore’s Intellectual Property practice group. He helps businesses, particularly in the technology sector, with patent litigation, patent prosecution, IP counselling, IP transactions, IP enforcement for MNC’s, export control, and various IP regulatory issues. He can be reached at cliu@fennemorelaw.com.

A Director in Fennemore’s Intellectual Property practice group, Dr. Paul Li counsels companies on how to protect and defend their intellectual property rights in U.S. and foreign institutions. In his comprehensive practice, he advises on patent prosecution, patent infringement assessment patent right licensing agreements, patentability, and intellectual property counseling and due diligence. He can be reached at zli@fennemorelaw.com.

Sources referenced

1. Supreme Court docket, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.: https://www.supremecourt.gov/docket/docketfiles/html/public/24-889.html
2. Supreme Court opinion PDF: https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
3. FDA: Abbreviated New Drug Application (ANDA): https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
4. FDA: Patent Certifications and Suitability Petitions: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions